Stockreport

SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System

SpyGlass Pharma, Inc.  (SGP) 
PDF 97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mea [Read more]